Search results
Results from the WOW.Com Content Network
[41] c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, [16] as is neurofibromatosis-1-associated wild-type GIST. [36] A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. [36] [42] Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. [43]
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
The TNM Classification of Malignant Tumors (TNM) is a globally recognised standard for classifying the anatomical extent of the spread of malignant tumours (cancer). It has gained wide international acceptance for many solid tumor cancers, but is not applicable to leukaemia or tumors of the central nervous system .
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. [1] It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient.
M8591/1 Sex cord-gonadal stromal tumor, incompletely differentiated M8592/1 Sex cord-gonadal stromal tumor, mixed forms M8593/1 Stromal tumor with minor sex cord elements M8600/0 Thecoma, NOS Theca cell tumor; M8600/3 Thecoma, malignant M8601/0 Thecoma, luteinized M8602/0 Sclerosing stromal tumor M8610/0 Luteoma, NOS Luteinoma
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. It is also used for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth ...